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Abstract
Many DNA variants have been identified on more than 300 diseases and traits using Genome-Wide Association Studies
(GWASs). Some have been validated using deep sequencing, but many fewer have been validated functionally, primarily
focused on non-synonymous coding SNPs (nsSNPs). It is an open question whether synonymous coding SNPs (sSNPs) and
other non-coding SNPs can lead to as high odds ratios as nsSNPs. We conducted a broad survey across 21,429 disease-SNP
associations curated from 2,113 publications studying human genetic association, and found that nsSNPs and sSNPs shared
similar likelihood and effect size for disease association. The enrichment of disease-associated SNPs around the 80
th base in
the first introns might provide an effective way to prioritize intronic SNPs for functional studies. We further found that the
likelihood of disease association was positively associated with the effect size across different types of SNPs, and SNPs in the
39untranslated regions, such as the microRNA binding sites, might be under-investigated. Our results suggest that sSNPs are
just as likely to be involved in disease mechanisms, so we recommend that sSNPs discovered from GWAS should also be
examined with functional studies.
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Introduction
Thousands of DNA variants have been identified on more than
300 diseases and traits in over 500 genome-wide association
studies (GWASs) in the past five years. Some of them have been
validated using high-quality deep sequencing, but many fewer of
them have been validated functionally. DNA variants that were
pursued for functional validation are usually those that were
predicted to lead to significant amino acid changes, such as non-
synonymous coding Single Nucleotide Polymorphism (nsSNPs). It
is an open question whether synonymous coding SNPs (sSNPs)
and other non-coding SNPs can lead to as high odds ratio as
nsSNPs.
To answer the question of relative significance of sSNPs and
nsSNPs, we need a catalog of known disease SNPs. There are
many current gene-based resources containing knowledge on
DNA variants associated with human diseases, such as The
Human Gene Mutation Database (HGMD) [1], Genetic Associ-
ation Database (GAD) [2], and Online Mendelian Inheritance in
Man (OMIM) [3]. However, most of these resources, such as GAD
and OMIM, do not report specific base-pair coordinates or
dbSNP IDs. As of this writing, the professional version of HGMD
only reports 1631 dbSNP IDs, which are embedded in free text
comments, and do not report other essential information, such as
p-value, odds ratio, and sample size.
Recently, the National Heart, Lung and Blood Institute (NHLBI)
[4] and National Human Genome Research Institute (NHGRI) [5]
released GWAS catalogs that were build from curated information
from the published literature reporting thousands of DNA variants
for human diseases. However, the NHLBI catalog only reports the
p-values for the associations, and does not report the effect sizes, as
indicated by the odds ratios. The NHGRI catalog does report both
the p-value and the odds ratio, but does not report the context of
that odds ratio, or specifically the two genotypes or alleles being
compared. We argue that both the likelihood and the effect size
need to be evaluated, and suggest that the effect size is going to be
more comparable across studies, due to its independence from the
sample size. In addition, both of these online catalogs ignore
candidate gene studies. A recent report[6] showed that genetic
associations proposed in the candidate gene era and replicated in
GWASs had significantly larger effect size than those newly
discovered in the GWASs, suggesting that the genetic associations
identified from candidate studies should not be discarded.
Furthermore, many candidate gene studies were performed in the
post GWAS era, by deep sequencing around GWAS loci.
Therefore, we found no comprehensive resource of human
disease-associated DNA variants covering both GWASs and
candidate studies, prior to this study.
We built a quantitative human disease-SNP association
database, curating from 2,113 publications. In this study, we
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effect size of human disease-SNP association among nine types of
SNPs, including nonsense, nsSNPs, sSNPs, and SNPs in the 59-
untranslated region (UTR), 39-UTR, near 59, near 39, intronic,
and intergenic regions.
Results
As previously described [7], starting from a list of Medline
abstracts that contains a dbSNP ID measured in the HapMap 3
projects[8], we manually curated 2,113 publications, and recorded
more than 100 features of the disease-SNP associations, including
the disease name (e.g. coronary artery disease), specific phenotype
(e.g. acute coronary syndrome in coronary artery disease), study
population(e.g. Portuguese), case and control population (Coro-
nary artery disease patients vs. healthy patients), genotyping
technology, major/minor alleles, odds ratio, 95% confidence
interval of the odds ratio, published p-value, and genetic model
(Fig. 1). By categorizing studies based on similar diseases, we
manually extracted the disease Medical Subject Heading (MESH)
terms [9], and mapped them to the Concept Unique Identifiers
(CUI) in the Unified Medical Language System (ULMS) [10] to
standardize disease names. We then annotated all SNPs using the
UCSC Genome Browser and NCBI Entrez to retrieve the
chromosome locations, functional types, and associated genes for
each.
As of this writing, we have cataloged 21,429 statistically
significant human disease-SNP associations from 2,113 publica-
tions. From this set, we found 45% of these variants had odds
ratios described in their publications (Table 1). Five thousand,
two hundred and seventy SNPs measured in the HapMap 3
project[8] were significantly associated with 375 different diseases,
which accounts for 0.13% SNPs and 7.28% genes measured in the
HapMap 3 project. Type 2 diabetes is the most studied diseases,
associated with 514 SNPs across 397 studies.
We evaluated the impact of SNP types on disease association
using the likelihood and effect size. We estimated the likelihood of
disease association for each SNP type using the percentage of
disease-associated SNPs known in the literature on two different
references. First, we calculated the likelihood of being associated
with human disease for six types of SNPs from the HapMap 3
project (Fig. 2). As expected, nonsense variants, which cause a
premature stop, were most likely to be associated with diseases
with 2.77% probability. Interestingly, 1.46% of nsSNPs, 1.38% of
SNPs within the 59-UTR region, and 1.26% of sSNPs (1.26%)
have also been known to associate with human disease. The result
indicates that sSNPs and SNPs in the 59-UTR regions were as
likely to be associated with disease as nsSNPs. Out of 5,272
HapMap SNPs that were statistically significantly associated with
disease, only 8.7% of them are nonsense or nsSNPs, causing
amino acid changes. If investigators attempt validation and
functional studies on amino-acid changing variants only, we
predict they will likely miss more than 90% disease-associated
variants.
Second, we calculated the likelihood of disease association for
each SNP type on six current human genotyping platforms
(Table 2). Similar with the results using the SNPs measured in the
HapMap 3 project, 2.28–16.67% of nonsense SNPs had been
discovered to associate with disease, which is significantly higher
than all other SNP types. Combing SNPs measured in all six
platforms, we found 2.10% of nonsense SNPs, 1.57% of nsSNPs,
1.35% of SNPs within 59-UTR, and 1.16% of sSNPs had been
reported to associate with human disease. Therefore, nsSNPs and
Figure 1. A curated quantitative disease-SNP association database. Starting from a list of all SNPs measured in the HapMap 3 project, we
searched for their presence in all Medline abstracts, eliminating non-human studies. Significant SNP-disease associations were manually curated from
the full text, and reviewed four rounds. SNP IDs were annotated using the UCSC genome browser for positions and function types and annotated
using Entrez for associated genes. Disease mesh terms were compared with the Unified Medical Language System (UMLS) to select concept unique
identifiers (CUIs).
doi:10.1371/journal.pone.0013574.g001
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disease on current genotyping platforms.
There were still 2,747 or 52% disease-associated SNPs within
the intronic regions; therefore, prioritizing disease SNPs in the
intronic region would be essential for the identification of novel
disease variants. Using gene annotations from the UCSC genome
browser we identified SNPs located within the first intron of a
gene, and their position relative to the start of the intron. We
analyzed all 1,497,869 HapMap intronic SNPs with all experi-
mentally validated transcripts and 31% of them fell into the first
intron. SNPs in the first intron were 1.2 times more likely to be
associated with disease than SNPs in the non-first introns
(p=2.2610
28, hypergeometric test). We then plotted the
cumulative density of disease SNPs along the first 1000 bases of
the first intron. The likelihood of disease association was
dramatically increased to a peak of 0.85% at the 80th bases,
quickly decreased back to 0.58% at the 180
th base, and gradually
stabilized at 0.5% (Fig. 3). Investigation around the 80
th base in
the first introns might provide an effective way to prioritize
intronic SNPs for functional studies.
We then evaluated the effect size of disease association among
nine SNP types by comparing the odds ratios of 9,574 disease-SNP
associations. As expected, nonsense SNPs had a median odds ratio
of 1.7660.227, significantly higher than those of all other SNP
types (p,0.05, Mann-Whitney U test, Fig. 4). Surprisingly,
nsSNPs shared a similar median odds ratio with sSNPs (1.72 vs.
1.70, p=0.24, Mann-Whitney U test), and had a significantly
higher median odds ratio than the remaining six SNP types, with
p-values ranging from 0.02 to 2610
-44. Therefore, nsSNPs and
sSNPs not only shared similar likelihood of disease association, but
also shared very similar effect size of disease association.
Finally, we plotted the likelihood against the median odds ratio
for all nine SNP types (Fig. 5). Interestingly, the effect size and
likelihood of disease associations fit almost perfectly along the
curve. The stronger diseases association a SNP type had, the more
likely it was to be associated with disease. The only outliers were
SNPs in the UTR regions. If we assumed that the association effect
size or odds ratios would not be changed when more studies were
performed, 39-UTR was clearly under-investigated for disease
association and 59-UTR was over-investigated.
Discussion
We conducted a broad survey across 21,429 human SNP-
disease associations curated from 2,113 publications, and com-
pared the likelihood and effect size of disease association among
Table 1. Statistics of the curated quantitative human disease-SNP association database.
Associations PubMed Diseases SNPs Genes
Percentage of genes in
HapMap3
All 21,429 2,113 375 5,270 1,588 7.28%
With odds ratio 9,574 1,255 292 2,764 1,003 4.60%
doi:10.1371/journal.pone.0013574.t001
Figure 2. Impact of SNP types on the likelihood of disease association. For each of the nine SNP types, the likelihood of disease associations
was estimated as the percentage of disease-associated SNPs among all SNPs measured in the HapMap 3 project. Similar likelihoods were observed
among nsSNPs, sSNPs, and SNPs in the 59-UTR. The number of disease-associated SNPs and SNPs measured in the HapMap 3 project were specified in
the parenthesis.
doi:10.1371/journal.pone.0013574.g002
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and effect size of human disease association compared to nsSNPs,
using SNPs measured in the HapMap 3 project and six current
genotyping platforms as the reference.
We acknowledge that these sSNPs might not be causal, but we
also found that they are not likely to be in linkage disequilibrium
(LD) with another undiscovered causal nsSNPs due to three
reasons. First, we curated the 21,429 SNP-disease associations
from the full text, tables, and abstracts in the publications, not
from the raw genotyping data. We suspect investigators would
have preferred and reported nsSNPs than sSNPs if the nsSNPs had
reached a threshold of statistical significance. Second, a recent
study suggested that uncommon or rare genetic variants can easily
create synthetic associations that are credited to common
variants[11]. If most reported sSNPs were synthetic from causal
nsSNPs, their effect size would be lower than that of nsSNPs,
which was different from our observation here. Furthermore,
many sSNPs had been consistently found to associate with human
disease in multiple different ethnicities, indicating that they were
not likely to be synthetic. For example, rs3810936, a synonymous
SNP in TNFSF15 was found to be significantly associated with
Crohn’s disease in Japanese[12,13], Korean[14], and Caucasian
[15]. Recently, several studies also suggested that synthetic
associations do not underlie many reported GWAS associa-
tions[16,17]. Finally, sSNPs might be causal through influencing
promoter activity and the conformation and stability of pre-
mRNAs[18], or changing the rate of protein folding[19]. A recent
review summarized the experimental evidence and mechanism on
how sSNPs altered the structure, function, and expression levels of
proteins[20]. Therefore, we believe that sSNPs are highly likely to
be involved in the disease mechanisms, and should be investigated
in the functional studies after GWASs.
We also found that the effect size of disease association was
positively associated with the likelihood of disease association for
Table 2. Likelihood of disease association for SNPs on current genotyping platforms.
Platform Nonsense nsSNP sSNP 59-UTR 39-UTR Near-gene-59 Near-gene_39 Intronic Intergenic
Affy 6.0 5.56% 2.51% 1.80% 2.15% 0.94% 0.63% 0.86% 0.27% 0.07%
Affy 5.0 16.67% 3.33% 2.29% 0.82% 0.84% 0.65% 1.09% 0.32% 0.10%
Affy 500k 16.67% 3.15% 2.19% 0.74% 0.76% 0.66% 1.02% 0.30% 0.10%
Illumina Omni1 3.05% 2.00% 1.31% 1.54% 1.01% 0.79% 1.29% 0.39% 0.12%
Illumina 1M 2.28% 1.85% 1.42% 1.56% 0.94% 0.89% 1.10% 0.38% 0.12%
Illumina 660W 3.12% 3.88% 2.37% 2.13% 1.74% 1.32% 1.56% 0.45% 0.16%
Combined array* 2.10% 1.57% 1.16% 1.35% 0.84% 0.71% 0.96% 0.30% 0.08%
*A hypothetical platform combined from the above six platforms to report the likelihood of SNPs being associate with human disease for each SNP type.
doi:10.1371/journal.pone.0013574.t002
Figure 3. Cumulative density of disease-associated SNPs in the first intron. The cumulative densities of disease-associated SNPs were
plotted against the distance from the first intron start site. The density was peaked at the 80
th base from the first intron start site.
doi:10.1371/journal.pone.0013574.g003
Synonymous SNPs for Disease
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size that a SNP has, the more likely it would have been discovered
with genome-wide significance. Interestingly, only limited number
of SNPs in the 39-UTR regions were discovered for disease
association in comparison with their relatively large effect sizes,
suggesting 39-UTR might be under-investigated. A recent study
analyzed the genome-wide gene expression on 270 HapMap
individuals and found that SNPs in the UTR regions showed
consistently increased population heterozygosity and were linked
with disease susceptibility[21]. Further investigation on SNPs in the
39-UTR region, especially the microRNA binding sites[22], will
likely identify many novel variants for missing heritability.
Figure 4. Impact of SNP types on the effect size of SNP-disease association. The median odds ratio6standard error was calculated for each
of the nine SNP types using 9,574 curated SNP-disease associations. The number of distinct SNPs was specified in the parenthesis. The odds ratios of
nonsense SNPs were significantly higher than those of other SNP types (p,0.05, Mann-whiney U test). The p-values between the odds ratios of
nsSNPs and other type of SNPs were shown in the figure.
doi:10.1371/journal.pone.0013574.g004
Figure 5. SNPs in the 39-UTR were under-investigated. The median odds ratio of SNP-disease associations was plotted against the percentage
of disease-associated SNPs for each of the nine SNP types. Assuming the median odds ratio will not be increased with more studies performed, the
percentage of disease-associated SNPs will likely be increased to fit the curve.
doi:10.1371/journal.pone.0013574.g005
Synonymous SNPs for Disease
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Curating human disease-associated DNA variants
As previously described[7], staring from a list of all SNPs
measured in the HapMap 3 project [8], we searched for the
presence of these rsIDs in all Medline abstracts, examined the full
text of these publications, and manually extracted SNPs that were
reported as statistically significantly associated with human disease.
We curated all SNPs described in the papers, but only SNPs that
were measured in the HapMap 3 project were used in this paper
[8]. For SNPs whose dbSNP IDs, or rsIDs were not reported in the
publications, they were manually compared with the sequences in
the NCBI Human dbSNP build 130 [23] to ensure a valid dbSNP
ID for every SNP in our database.
Categorizing studies on similar diseases
To enable the integration of multiple studies on similar diseases,
we mapped the disease/phenotype names in our association
database to the Unified Medical Language System (UMLS)
Concept Unique Identifiers (CUIs) [10]. To ensure the difficult
process of matching disease names to UMLS CUI was performed
with high quality, we manually selected the best descriptive disease
names from the Medical Subject Heading (MeSH) terms [9]
associated with each paper during the curation, and manually
examined the matching UMLS CUIs. Gradually, we built up a
standardized list of commonly studied disease names, which
smoothed the automated post-processing.
Annotating and categorizing SNPs
All SNPs measured in the HapMap 3 project were annotated
using the UCSC genome browser [24] with the dbSNP build 130
to retrieve their physical locations and functional types. SNPs that
were located within or near a gene were annotated using the NCBI
Entrez. We parsed the ‘‘Known Genes’’ track of the UCSC
genome browser[24] and extracted intron annotations from each
gene, noting the index of each intron in the direction of
transcription. All intronic SNPs were mapped to transcripts and
labeled according to whether they fell inside the first intron and by
distance from the intron start site.
Calculating likelihood and effect size of disease
association
We estimated the likelihood of disease association as the
percentage of SNPs being associated with human disease among
all SNPs measured in the HapMap 3 project or six genotyping
platforms, including Affymetrix Human GenomeWide SNP arrays
(6.0, 5.0, & 500K), and Illumina Human Omni1-Quad1, 1M-
Duov3, and 660W-Quadv1. All annotation files were downloaded
from Affymetrix and Illumina company web sites. The effect size
of disease association was estimated as the median odds ratio
among all curated SNP-disease associations for each SNP type.
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